A New Investigational Perspective for Purines Against Glioblastoma Invasiveness

Curr Drug Targets. 2018;19(16):1871-1881. doi: 10.2174/1389450119666180226123819.

Abstract

Background: Glioblastoma Multiforme (GBM) is the most common and lethal brain malignancy. Recent evidence suggests that the presence of stem-like cells (GSCs) inside the tumor with high self-renewal, resistance to chemotherapy and invasiveness/migration potential is associated with poor GBM prognosis. GSC aggressiveness seems to be linked to an important process involved in tumorigenesis and cancer metastasis called Epithelial-to-Mesenchymal Transition (EMT), which is responsible for several biochemical changes and the acquisition of a more mesenchymal phenotype by GSCs, that enhance their migration, invasiveness and resistance to apoptosis.

Objective: Since previous reports demonstrated that purines, interacting with their own receptors, exerted anti-tumor effects in GBM and derived cells, we tried to investigate the ability of these compounds to reduce tumor cell migration/invasion acting on EMT-associated genes/activators and/or signal pathways.

Methods: Search in the literature of relevant articles related to the objective.

Results: Papers examining the activity of purines on EMT signaling pathways/markers in GSCs are still few whereas literature is more abundant as for other kinds of tumors.

Conclusion: Considering the significance of EMT in GBM aggressiveness and the promising involvement of purines in this process, we think that further research in this regard may open the way towards a new therapeutic approach for the control of GBM invasiveness/recurrence.

Keywords: EMT markers; Glioblastoma multiforme; adenine-based purines; epithelial-to-mesenchymal transition (EMT); glioblastoma-derived stem cells; purine receptors..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Cell Movement / drug effects
  • Clinical Trials as Topic
  • Epithelial-Mesenchymal Transition / drug effects
  • Glioblastoma / drug therapy*
  • Glioblastoma / pathology
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasm Invasiveness / prevention & control
  • Purinergic Antagonists / pharmacology*
  • Purinergic Antagonists / therapeutic use
  • Purines / pharmacology
  • Purines / therapeutic use*
  • Receptors, Purinergic / metabolism
  • Signal Transduction / drug effects
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Purinergic Antagonists
  • Purines
  • Receptors, Purinergic